Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IDEXX Laboratories

McKesson

Thermo Fisher Scientific

Here are a few MedTech companies which have outperformed the S&P 500 index in the past two months.

Coronavirus Hits S&P 500: 4 MedTech Stocks That Fared Better

America Movil SAB de CV

DaVita

TEGNA

Volatility is likely to persist in April as the panoptic impact of the coronavirus outbreak is yet to be realized in the United States and globally.

5 Top Value Stocks to Buy in a Volatile April

Medtronic

ResMed

COVID-19 has increased the demand for ventilators and personal protective equipment, which can aid these three companies at large.

3 Must-Buy Stocks as Coronavirus Cases Spike (Revised)

Cardinal Health: Future Dividend Aristocrat

AbbVie

Automatic Data Processing

Aflac

A. O. Smith

Becton, Dickinson and Co.

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Chubb

Colgate-Palmolive

Dover

Ecolab

Emerson Electric

General Dynamics

Genuine Parts

Johnson & Johnson

McDonald's

McCormick

Nucor

Walgreens

In times of market turmoil, one group of stocks that investors can count on to deliver reliable income growth is the Dividend Aristocrats: an elite group of companies that have produced at least 25 consecutive years of dividend hikes.

19 Dividend Aristocrats That Have Gone on Deep Discount

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and strategic buyouts.

Why You Should Invest in Cardinal Health (CAH) Stock Now

3 Must-Buy Stocks as Coronavirus Cases Spike

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Cardinal Health (CAH) a Great Value Stock Right Now?

Bristol-Myers

MarketAxess Holdings

UnitedHealth Group

Stocks have fallen significantly in a short period of time and several of them offer lucrative buying opportunity at this stage.

5 Top Picks to Tap the Dow and S&P 500's Back-to-Back Rally

Campbell Soup

Duke Energy

MDU Resources Group

Patterson Companies

Procter & Gamble

The coronavirus pandemic is spooking investors, making them hunt for safe stocks to invest. Here are six defensive stocks that provide stable dividends.

6 Stocks to Buy Despite Coronavirus-Driven Market Volatility

Visa

These two stocks can offer investors a good mix of growth and dividends.

2 Dividend Stocks  You Can Safely Hold for Decades

Applied Materials

eBay

KB Home

Lennar

PulteGroup

Regeneron Pharmaceuticals

Western Digital

Despite the virus-driven global disturbance, the U.S. economy remains stable as indicated by recently released various data for the month of February.

How to Invest in a Volatile Market Amid a Stable U.S. Economy

Cardinal (CAH) reported earnings 30 days ago. What's next for the stock?

Why Is Cardinal (CAH) Down 12% Since Last Earnings Report?

As of late, it has definitely been a great time to be an investor Cardinal Health.

Will Cardinal Health Continue to Surge Higher?

Cardinal Health (CAH) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Is Cardinal Health (CAH) Stock a Solid Choice Right Now?

Cardinal (CAH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Cardinal (CAH) Upgraded to Strong Buy: Here's Why

United Therapeutics

Virtusa

A lower PEG ratio, preferably less than 1, indicates both undervaluation and solid future growth potential of a stock.

4 Finest Value Stocks Based on Discounted PEG

Abercrombie & Fitch

Anixter

Brookdale Senior Living

Fluor

One of the well-accepted investment policies is to maintain a diversified portfolio for reaping handsome returns, irrespective of the market volatility.

5 Broker-Friendly Stocks to Ride Out the Coronavirus Scare

Cardinal Health (CAH) seems to be a good value pick, as it has decent revenue metrics to back up its earnings, and is seeing solid earnings estimate revisions as well.

Looking for Value? Why It Might Be Time to Try Cardinal Health (CAH)

American Equity Investment Life

Blackrock Inc

Top Ranked Momentum Stocks to Buy for February 20th

AmerisourceBergen

Leading drug distributor stocks remain sensitive to ongoing opioid settlement negotiations. Here are crucial technical levels to watch.

Drug Distributor Stocks in Focus on Opioid Settlement News

Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment.

Here's Why You Should Invest in Cardinal Health Stock Now

The three big drug distributors have been in talks for months in the hopes of finding a global settlement.

21 States Reject $18 Billion Bid to Settle Opioid Litigation

Shares of drug wholesalers, who have held talks to settle opioid litigation, sank in morning trading Friday, after The Wall Street Journal reported that 21 states had rejected an $18 billion settlement offer. Shares of AmerisourceBergen Corp.

Drug wholesaler stocks falls after WSJ report that states rejected opioid settlement offer

News for Cardinal Health Stock (CAH)